Back to the journal

Peptides

The Oct 28 peptide notice is a draft

The Oct 28 peptide notice is a draft

4 min read

Short answer. The document filed on Oct 28, 2026 is a notice that a draft policy is available. The notice says that draft does not establish any rights for any person and is not binding on HHS or the public [1]. As of Oct 29, 2026.

What was filed

Item

What the notice prints

Action

Notice of availability

Document number

FR Doc. 2026-22192

Docket

HHS-OASH-2026-0496

Filed

Oct 28, 2026, 11:15 a.m.

Scheduled publication

Oct 30, 2026

Signature

Robert F. Kennedy, Jr., Secretary

Public inspection is not the official Federal Register edition. The notice itself says it is scheduled to be published on Oct 30, 2026 [1]. Until that official edition exists, the public-inspection PDF is the document HHS filed.

Draft, in the notice's words

The supplementary information calls the policy a draft. Then it says the draft does not establish any rights for any person and is not binding on HHS or the public [1].

That is different from a final rule that adds a substance to the 503A bulks list. The notice says future FDA rulemakings may propose adding some or all of these peptides to that list [1]. "May" is the notice's word.

HHS may also revisit the interim policy, in whole or in part, if a safety signal or a product-quality issue arises [1].

Comments can be submitted until two weeks after publication in the Federal Register, on the docket above, through regulations.gov [1]. A comment does not rewrite the policy by itself.

The peptide names, forms, and conditions are in the policy PDF the notice links [2]. The plain-language version of the core sentence is in Enforcement discretion, in plain language.

FAQ

Is the policy final because it was on the news? No. The notice calls it a draft and says it is not binding [1].

Did publication on Oct 28 make it official? The notice was filed for public inspection on Oct 28. It prints a publication date of Oct 30, 2026 [1].

Sources

  1. HHS notice of availability, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

  2. HHS policy PDF linked from that notice. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Sommar Club does not prescribe or sell these six peptides. Education only. Not medical or legal advice. As of Oct 29, 2026.

Three minutes tonight.

Answer a few questions. Hear back from a clinician, usually within a day.

See if you qualifyFree online visit. Pay nothing unless approved.
Sommar Club NAD+ editorial product conceptNAD+
Sommar Club GLP-1 CARE editorial product conceptGLP-1 CARE
Sommar Club SERMORELIN editorial product conceptSERMORELIN